Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription 27.02.2023 1 Am J Clin Oncol 1 Ann Surg Oncol 1 Ann Thorac Surg 1 Arch Bronconeumol 2 Cancer 2 Clin Cancer Res 1 Clin Lung Cancer 1 Eur J Cancer 1 Eur J Cardiothorac Surg 2 Int J Radiat Oncol Biol Phys 4 J Cancer Res Clin Oncol 5 J Clin Oncol 4 JAMA Oncol 7 Lung Cancer 1 Oncogene 1 Oncologist 3 PLoS One 2 Proc Natl Acad Sci U S A 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. HU YX, Guo LJ, Lin MQ, Lin QY, et al
   Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer.
   Am J Clin Oncol. 2023 Feb 20. doi: 10.1097/COC.0000000000000985.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. MA H, Li S, Zhu Y, Zhang W, et al
   A Novel Prognostic Score Based on Multiple Quantitative Parameters of Chest CT for Patients with Synchronous Multiple Primary Lung Cancer: Is Solid Component Size a Better Prognostic Indicator?
   Ann Surg Oncol. 2023 Feb 23. doi: 10.1245/s10434-023-13248.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

3. ZHOU N, Niu J, Nelson D, Feldman HA, et al
   Surgical Approach and Persistent Opioid Use in Medicare Patients undergoing Lung Cancer Resection.
   Ann Thorac Surg. 2023 Feb 15:S0003-4975(23)00138.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

4. CASTRO BARBOSA A, Silva A, Pignatelli A
   Lung Cancer: A Frequent Tumor With a Rare Synchronous Metastasis.
   Arch Bronconeumol. 2023 Feb 6:S0300-2896(23)00024.
   PubMed        
   
   

   
   Cancer

5. HE J, Ma P, Zhao D, Shi X, et al
   Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
   Cancer. 2023 Feb 22. doi: 10.1002/cncr.34697.
   PubMed         Abstract available
   
   
6. ERNANI V, Appiah AK, Rodriguez D, Kusne Y, et al
   Lobar versus sublobar resection for atypical lung carcinoid: An analysis from the National Cancer Database.
   Cancer. 2023;129:860-866.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

7. WIJETUNGA NA, Goglia AG, Weinhold N, Berger MF, et al
   Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases.
   Clin Cancer Res. 2023;29:775-783.
   PubMed         Abstract available
   
   
8. OWEN DH, Benner B, Wei L, Sukrithan V, et al
   A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
   Clin Cancer Res. 2023;29:731-741.
   PubMed         Abstract available
   
   

   
   Clin Lung Cancer

9. SEBASTIAN NT, Stokes WA, Behera M, Jiang R, et al
   The Association of Improved Overall Survival with NSAIDs in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
   Clin Lung Cancer. 2023 Jan 21:S1525-7304(23)00001.
   PubMed         Abstract available
   
   

   
   Eur J Cancer

10. BYLICKI O, Tomasini P, Radj G, Guisier F, et al
    Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II o
    Eur J Cancer. 2023;183:38-48.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

11. GOSSOT D, Lafouasse C, Kovacs E, Seguin-Givelet A, et al
    Sublobar resection for early-stage lung cancer: the issue of safety margins.
    Eur J Cardiothorac Surg. 2023 Feb 22:ezad055. doi: 10.1093.
    PubMed        
    
    

    
    Int J Radiat Oncol Biol Phys

12. NAKAMURA M, Kageyama SI, Hirata H, Tochinai T, et al
    Detection of pretreatment circulating tumor DNA predicts recurrence after high-dose proton beam therapy for early-stage non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Feb 21:S0360-3016(23)00166.
    PubMed         Abstract available
    
    
13. KATZ MS, Weissferdt A, Antonoff MB
    Histologic Subtypes of Non-Small Cell Lung Cancer: Can We Further Personalize Radiation Therapy?
    Int J Radiat Oncol Biol Phys. 2023;115:906-908.
    PubMed        
    
    

    
    J Cancer Res Clin Oncol

14. SHAO F, Ling L, Li C, Huang X, et al
    Establishing a metastasis-related diagnosis and prognosis model for lung adenocarcinoma through CRISPR library and TCGA database.
    J Cancer Res Clin Oncol. 2023;149:885-899.
    PubMed         Abstract available
    
    
15. WU Z, Wang Y, Jin L, Wei J, et al
    Case report: identification of EGFR R776H and FANCE R381H germline mutations in a patient with multiple pulmonary nodules.
    J Cancer Res Clin Oncol. 2023;149:921-927.
    PubMed         Abstract available
    
    
16. YAO N, Pan J, Chen X, Li P, et al
    Discovery of potential biomarkers for lung cancer classification based on human proteome microarrays using Stochastic Gradient Boosting approach.
    J Cancer Res Clin Oncol. 2023 Feb 18. doi: 10.1007/s00432-023-04643.
    PubMed         Abstract available
    
    
17. LI C, Li J, Xiong S, Zhou H, et al
    Risk mapping of lung cancer: a comprehensive appraisal of published meta-analyses incorporating Mendelian randomization studies.
    J Cancer Res Clin Oncol. 2023 Feb 21. doi: 10.1007/s00432-023-04606.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

18. SANCHEZ-MAGRANER L, Gumuzio J, Miles J, Quimi N, et al
    Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2023 Feb 23:JCO2201748. doi: 10.1200/JCO.22.01748.
    PubMed         Abstract available
    
    
19. DEEK MP, Haigentz M, Jabbour SK
    Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same.
    J Clin Oncol. 2023 Feb 23:JCO2202316. doi: 10.1200/JCO.22.02316.
    PubMed         Abstract available
    
    
20. GARASSINO MC, Gadgeel S, Speranza G, Felip E, et al
    Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
    J Clin Oncol. 2023 Feb 21:JCO2201989. doi: 10.1200/JCO.22.01989.
    PubMed         Abstract available
    
    
21. JAIYESIMI IA, Owen DH, Ismaila N, Blanchard E, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3.
    J Clin Oncol. 2023 Feb 21:JCO2202783. doi: 10.1200/JCO.22.02783.
    PubMed         Abstract available
    
    
22. JAIYESIMI IA, Owen DH, Ismaila N, Blanchard E, et al
    Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3.
    J Clin Oncol. 2023 Feb 21:JCO2202782. doi: 10.1200/JCO.22.02782.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

23. BAO Y, Zhang H, Bruera E, Portenoy R, et al
    Medical Marijuana Legalization and Opioid- and Pain-Related Outcomes Among Patients Newly Diagnosed With Cancer Receiving Anticancer Treatment.
    JAMA Oncol. 2023;9:206-214.
    PubMed         Abstract available
    
    
24. YAP DWT, Leone AG, Wong NZH, Zhao JJ, et al
    Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    JAMA Oncol. 2023;9:215-224.
    PubMed         Abstract available
    
    
25. YOON HH, Shi Q, Ajani JA
    Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply.
    JAMA Oncol. 2023;9:280-281.
    PubMed        
    
    
26. ZHANG X, Ning C, Zhao H
    Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer.
    JAMA Oncol. 2023;9:280.
    PubMed        
    
    

    
    Lung Cancer

27. KANG J, Deng QM, Feng W, Chen ZH, et al
    Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.
    Lung Cancer. 2023;178:66-74.
    PubMed         Abstract available
    
    
28. BRANDAO M, Durieux V, Auprih M, Fozza A, et al
    Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection - A systematic review.
    Lung Cancer. 2023;178:75-86.
    PubMed         Abstract available
    
    
29. CHENG Y, Zhou Q, Han B, Fan Y, et al
    NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.
    Lung Cancer. 2023;178:87-95.
    PubMed         Abstract available
    
    
30. KIEVIT H, Muntinghe-Wagenaar MB, Hijmering-Kappelle LBM, Hiddinga BI, et al
    Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial.
    Lung Cancer. 2023;178:96-102.
    PubMed         Abstract available
    
    
31. LANGSTON J, Patil T, Ross Camidge D, Bunn PA, et al
    CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.
    Lung Cancer. 2023;178:103-107.
    PubMed         Abstract available
    
    
32. BUTTER R, Halfwerk H, Radonic T, Lissenberg-Witte B, et al
    The impact of impaired tissue fixation in resected non-small-cell lung cancer on protein deterioration and DNA degradation.
    Lung Cancer. 2023;178:108-115.
    PubMed         Abstract available
    
    
33. AUCLIN E, Benitez-Montanez J, Tagliamento M, Parisi F, et al
    Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2023;178:116-122.
    PubMed         Abstract available
    
    

    
    Oncogene

34. LIU B, Zhang J, Meng X, Xie SM, et al
    HDAC6-G3BP2 promotes lysosomal-TSC2 and suppresses mTORC1 under ETV4 targeting-induced low-lactate stress in non-small cell lung cancer.
    Oncogene. 2023 Feb 23. doi: 10.1038/s41388-023-02641.
    PubMed         Abstract available
    
    

    
    Oncologist

35. NOVELLO S, Califano R, Reinmuth N, Tamma A, et al
    RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
    Oncologist. 2023 Feb 23:oyac264. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

36. ANDERSEN BL, Myers J, Blevins T, Park KR, et al
    Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival.
    PLoS One. 2023;18:e0282206.
    PubMed         Abstract available
    
    
37. SAITO T, Hamakawa A, Takahashi H, Muto Y, et al
    Symptom severity trajectories and distresses in patients undergoing video-assisted thoracoscopic lung resection from surgery to the first post-discharge clinic visit.
    PLoS One. 2023;18:e0281998.
    PubMed         Abstract available
    
    
38. WILLIAMS CD, Allo MA, Gu L, Vashistha V, et al
    Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
    PLoS One. 2023;18:e0282020.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

39. JANSSEN K, Claes F, Van de Velde D, Wehbi VL, et al
    Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein.
    Proc Natl Acad Sci U S A. 2023;120:e2214921120.
    PubMed         Abstract available
    
    
40. ZHANG Z, Lu YX, Liu F, Sang L, et al
    lncRNA BREA2 promotes metastasis by disrupting the WWP2-mediated ubiquitination of Notch1.
    Proc Natl Acad Sci U S A. 2023;120:e2206694120.
    PubMed         Abstract available
    
    

    
    Thorax

41. BENNETT K, Totton K, Misacas A, Caswell F, et al
    Transient visual loss following CT-guided percutaneous core needle biopsy of a lung lesion.
    Thorax. 2023;78:316-317.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: